ATG9B and colorectal carcinoma: Simultaneously, adding MG132 to inhibit the degradation of ATG9B caused by the reduction of MYH9 will restore a part of invasion, but it is still weaker than the control group, indicating that ATG9B depends on MYH9 to promote CRC invasion (Fig. 4N).